vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Idaho Strategic Resources, Inc. (IDR). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $14.6M, roughly 1.1× Idaho Strategic Resources, Inc.). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs -7.8%, a 72.0% gap on every dollar of revenue. On growth, Idaho Strategic Resources, Inc. posted the faster year-over-year revenue change (92.0% vs 27.3%). Over the past eight quarters, Idaho Strategic Resources, Inc.'s revenue compounded faster (57.2% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Idaho Strategic Resources, Inc.IDREarnings & Financial Report
Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.
DERM vs IDR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $14.6M |
| Net Profit | $-1.2M | $9.4M |
| Gross Margin | — | 68.5% |
| Operating Margin | -2.8% | 62.4% |
| Net Margin | -7.8% | 64.3% |
| Revenue YoY | 27.3% | 92.0% |
| Net Profit YoY | -182.0% | 220.6% |
| EPS (diluted) | $-0.04 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $14.6M | ||
| Q3 25 | $17.0M | $11.1M | ||
| Q2 25 | $15.0M | $9.5M | ||
| Q1 25 | $13.1M | $7.3M | ||
| Q4 24 | $12.6M | $7.6M | ||
| Q3 24 | $14.6M | $6.2M | ||
| Q2 24 | $14.9M | $6.1M | ||
| Q1 24 | $13.0M | $5.9M |
| Q4 25 | $-1.2M | $9.4M | ||
| Q3 25 | $-2.3M | $3.0M | ||
| Q2 25 | $-3.8M | $2.8M | ||
| Q1 25 | $-4.1M | $1.6M | ||
| Q4 24 | $1.5M | $2.9M | ||
| Q3 24 | $-2.4M | $1.6M | ||
| Q2 24 | $-3.4M | $2.2M | ||
| Q1 24 | $-10.4M | $2.2M |
| Q4 25 | — | 68.5% | ||
| Q3 25 | — | 63.6% | ||
| Q2 25 | — | 57.8% | ||
| Q1 25 | — | 50.8% | ||
| Q4 24 | 82.3% | 53.3% | ||
| Q3 24 | 63.9% | 48.7% | ||
| Q2 24 | 56.0% | 50.2% | ||
| Q1 24 | 47.7% | 48.1% |
| Q4 25 | -2.8% | 62.4% | ||
| Q3 25 | -9.0% | 23.4% | ||
| Q2 25 | -19.2% | 26.6% | ||
| Q1 25 | -25.3% | 19.3% | ||
| Q4 24 | 17.7% | 36.2% | ||
| Q3 24 | -19.8% | 23.4% | ||
| Q2 24 | -19.7% | 34.2% | ||
| Q1 24 | -77.4% | 36.3% |
| Q4 25 | -7.8% | 64.3% | ||
| Q3 25 | -13.6% | 26.8% | ||
| Q2 25 | -25.3% | 29.2% | ||
| Q1 25 | -31.0% | 22.1% | ||
| Q4 24 | 12.1% | 38.5% | ||
| Q3 24 | -16.3% | 25.8% | ||
| Q2 24 | -22.6% | 35.2% | ||
| Q1 24 | -80.1% | 36.8% |
| Q4 25 | $-0.04 | $0.62 | ||
| Q3 25 | $-0.09 | $0.20 | ||
| Q2 25 | $-0.16 | $0.20 | ||
| Q1 25 | $-0.18 | $0.12 | ||
| Q4 24 | $0.10 | $0.21 | ||
| Q3 24 | $-0.12 | $0.12 | ||
| Q2 24 | $-0.17 | $0.17 | ||
| Q1 24 | $-0.53 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | — |
| Total DebtLower is stronger | $25.3M | $2.3M |
| Stockholders' EquityBook value | $31.9M | $108.2M |
| Total Assets | $94.6M | $116.2M |
| Debt / EquityLower = less leverage | 0.79× | 0.02× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | — | ||
| Q3 25 | $24.9M | — | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $21.1M | — | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $23.9M | $6.3M | ||
| Q1 24 | $24.1M | $5.3M |
| Q4 25 | $25.3M | $2.3M | ||
| Q3 25 | $25.2M | $3.0M | ||
| Q2 25 | $25.1M | $3.3M | ||
| Q1 25 | $25.0M | $3.7M | ||
| Q4 24 | $24.9M | $1.7M | ||
| Q3 24 | $19.8M | $2.9M | ||
| Q2 24 | $19.7M | $2.7M | ||
| Q1 24 | $14.7M | $3.3M |
| Q4 25 | $31.9M | $108.2M | ||
| Q3 25 | $25.9M | $74.3M | ||
| Q2 25 | $19.2M | $49.3M | ||
| Q1 25 | $21.5M | $39.8M | ||
| Q4 24 | $20.1M | $37.7M | ||
| Q3 24 | $10.9M | $33.1M | ||
| Q2 24 | $11.3M | $25.4M | ||
| Q1 24 | $13.0M | $21.6M |
| Q4 25 | $94.6M | $116.2M | ||
| Q3 25 | $85.2M | $83.1M | ||
| Q2 25 | $81.2M | $57.7M | ||
| Q1 25 | $85.0M | $48.1M | ||
| Q4 24 | $80.2M | $44.0M | ||
| Q3 24 | $64.0M | $40.8M | ||
| Q2 24 | $65.2M | $32.2M | ||
| Q1 24 | $66.6M | $28.7M |
| Q4 25 | 0.79× | 0.02× | ||
| Q3 25 | 0.97× | 0.04× | ||
| Q2 25 | 1.30× | 0.07× | ||
| Q1 25 | 1.16× | 0.09× | ||
| Q4 24 | 1.24× | 0.05× | ||
| Q3 24 | 1.81× | 0.09× | ||
| Q2 24 | 1.75× | 0.11× | ||
| Q1 24 | 1.13× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $10.7M |
| Free Cash FlowOCF − Capex | — | $8.2M |
| FCF MarginFCF / Revenue | — | 56.0% |
| Capex IntensityCapex / Revenue | — | 17.7% |
| Cash ConversionOCF / Net Profit | — | 1.15× |
| TTM Free Cash FlowTrailing 4 quarters | — | $12.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $10.7M | ||
| Q3 25 | $-2.4M | $2.4M | ||
| Q2 25 | $-942.0K | $3.5M | ||
| Q1 25 | $-2.8M | $2.4M | ||
| Q4 24 | $2.2M | $3.2M | ||
| Q3 24 | $-1.2M | $2.5M | ||
| Q2 24 | $-5.2M | $2.6M | ||
| Q1 24 | $-5.0M | $2.6M |
| Q4 25 | — | $8.2M | ||
| Q3 25 | — | $709.8K | ||
| Q2 25 | — | $2.5M | ||
| Q1 25 | — | $1.0M | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | — | $1.9M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | $2.3M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | — | 26.5% | ||
| Q1 25 | — | 13.8% | ||
| Q4 24 | — | 28.0% | ||
| Q3 24 | — | 30.4% | ||
| Q2 24 | — | 38.7% | ||
| Q1 24 | — | 38.3% |
| Q4 25 | — | 17.7% | ||
| Q3 25 | — | 15.3% | ||
| Q2 25 | — | 10.8% | ||
| Q1 25 | — | 19.4% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | 5.5% |
| Q4 25 | — | 1.15× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 1.28× | ||
| Q1 25 | — | 1.50× | ||
| Q4 24 | 1.46× | 1.08× | ||
| Q3 24 | — | 1.56× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | — | 1.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
IDR
Segment breakdown not available.
